BridgeMD
New treatment option for Age-Related Macular Degeneration
Official title Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
ClinicalTrials.gov ID: NCT06087458
What this study is testing
What is VOY-101?
VOY-101 is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for age-related macular degeneration.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 60 and older
You may be able to join if
- Are ≥60 years of age at the time of consent.
- Are willing and able to understand and provide written informed consent.
- Are willing and able to return for scheduled treatment and follow-up examinations.
- Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
- Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes.
You likely can't join if
- Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the...
- Additional Systemic, Ocular, and Genetic Exclusion Criteria.
See the full eligibility criteria
- Are ≥60 years of age at the time of consent.
- Are willing and able to understand and provide written informed consent.
- Are willing and able to return for scheduled treatment and follow-up examinations.
- Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
- Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes.
- Absence of signs of non-exudative MNV.
- Additional Ocular for both eyes.
- Meet certain genotype criteria for risk of AMD.
- Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.
- Additional Systemic, Ocular, and Genetic Exclusion Criteria.
The study team makes the final eligibility decision.
Where it's taking place
- Scottsdale, Arizona, United States
- Encino, California, United States
- Sacramento, California, United States
- San Diego, California, United States
- Burleson, Texas, United States
- Southlake, Texas, United States
- Salt Lake City, Utah, United States
- Sydney, New South Wales, Australia
- East Melbourne, Victoria, Australia
- Haifa, Israel
- Tel Aviv, Israel
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 60 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Scottsdale, Arizona, United States; Encino, California, United States; Sacramento, California, United States; San Diego, California, United States; Burleson, Texas, United States; Southlake, Texas, United States and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.